Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-019050
Filing Date
2023-11-14
Accepted
2023-11-14 16:42:03
Documents
108
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q fbio-20230930x10q.htm   iXBRL 10-Q 4214144
2 EX-31.1 fbio-20230930xex31d1.htm EX-31.1 13878
3 EX-31.2 fbio-20230930xex31d2.htm EX-31.2 14562
4 EX-32.1 fbio-20230930xex32d1.htm EX-32.1 8190
5 EX-32.2 fbio-20230930xex32d2.htm EX-32.2 8127
  Complete submission text file 0001558370-23-019050.txt   16527205

Data Files

Seq Description Document Type Size
6 EX-101.SCH fbio-20230930.xsd EX-101.SCH 114287
7 EX-101.CAL fbio-20230930_cal.xml EX-101.CAL 98879
8 EX-101.DEF fbio-20230930_def.xml EX-101.DEF 513379
9 EX-101.LAB fbio-20230930_lab.xml EX-101.LAB 811989
10 EX-101.PRE fbio-20230930_pre.xml EX-101.PRE 750707
102 EXTRACTED XBRL INSTANCE DOCUMENT fbio-20230930x10q_htm.xml XML 3092673
Mailing Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154
Business Address 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 781-652-4500
Fortress Biotech, Inc. (Filer) CIK: 0001429260 (see all company filings)

EIN.: 205157386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35366 | Film No.: 231407316
SIC: 2834 Pharmaceutical Preparations